{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:16:17Z","timestamp":1790806577620,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108576","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T07:54:43Z","timestamp":1725954883000},"page":"108576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genotype\u2013phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey"],"prefix":"10.1016","volume":"143","author":[{"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Amartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Audi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fertek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Merberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudan","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.H.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2024.108576_bb0005","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","author":"Tylki-Szyma\u0144ska","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108576_bb0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108576_bb0015","article-title":"Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev. (Pavia)"},{"issue":"suppl","key":"10.1016\/j.ymgme.2024.108576_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgme.2017.09.011","article-title":"Surgical management of neurological manifestations of mucopolysaccharidosis disorders","volume":"122","author":"Alden","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 5","key":"10.1016\/j.ymgme.2024.108576_bb0025","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108576_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108576_bb0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108576_bb0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108576_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108576_bb0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108576_bb0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108576_bb0065","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"issue":"suppl","key":"10.1016\/j.ymgme.2024.108576_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations \u2014 neurological signs and symptoms","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108576_bb0075","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108576_bb0080","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","article-title":"Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management","volume":"34","author":"Braunlin","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"455","key":"10.1016\/j.ymgme.2024.108576_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2024.108576_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108392","article-title":"A molecular genetics view on mucopolysaccharidosis type II","volume":"788","author":"Verma","year":"2021","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108576_bb0095","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","article-title":"Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: genetic, pathological, and structural studies on iduronate-2-sulfatase","volume":"118","author":"Kosuga","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108576_bb0100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype\u2013phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108576_bb0105","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype\u2013phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2024.108576_bb0110","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0115","first-page":"71","article-title":"Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II)","volume":"14","author":"Semyachkina","year":"2021","journal-title":"BMC Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108576_bb0120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajmg.c.31915","article-title":"Genotype\u2013phenotype studies in a large cohort of Brazilian patients with Hunter syndrome","volume":"187","author":"Josahkian","year":"2021","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108576_bb0125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1750-1172-8-92","article-title":"Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study","volume":"8","author":"Guillen-Navarro","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108576_bb0130","series-title":"Sequence Variant Nomenclature","year":"2023"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108576_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.36469\/jheor.2022.36540","article-title":"Impact of the timing of enzyme replacement therapy initiation and cognitive impairment status on outcomes for patients with mucopolysaccharidosis II (MPS II) in the United States: a retrospective chart review","volume":"9","author":"Yee","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"issue":"220","key":"10.1016\/j.ymgme.2024.108576_bb0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/adc.41.220.613","article-title":"Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch. Dis. Child."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108576_bb0145","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbadis.2006.01.003","article-title":"Identification of nine new IDS alleles in mucopolysaccharidosis II. Quantitative evaluation by real-time RT-PCR of mRNAs sensitive to nonsense-mediated and nonstop decay mechanisms","volume":"1762","author":"Lualdi","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/humu.1380050114","article-title":"Mutations of the iduronate-2-sulfatase gene in 12 Polish patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"5","author":"Popowska","year":"1995","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108576_bb0155","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis","volume":"29","author":"Sukegawa-Hayasaka","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108576_bb0160","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-006-0403-z","article-title":"Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations","volume":"29","author":"Alves","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108576_bb0165","first-page":"1202","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): mutation \u201chot spots\u201d in the iduronate-2-sulfatase gene","volume":"59","author":"Rathmann","year":"1996","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0170","first-page":"21","article-title":"Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"36","author":"Li","year":"1999","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ijms21010114","article-title":"Identification and functional characterization of IDS gene mutations underlying Taiwanese Hunter syndrome (mucopolysaccharidosis type II)","volume":"21","author":"Lin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108576_bb0180","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108576_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ijns8040055","article-title":"Addition of MPS-II to the recommended uniform screening panel in the United States","volume":"8","author":"Millington","year":"2022","journal-title":"Int. J. Neonatal Screen."},{"issue":"suppl","key":"10.1016\/j.ymgme.2024.108576_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2017.09.007","article-title":"Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108576_bb0195","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13023-021-02118-3","article-title":"Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II","volume":"16","author":"Yee","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2024.108576_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"van der Lee","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:21:06Z","timestamp":1742437266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":40,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004608"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108576","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype\u2013phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Takeda. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108576"}}